Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) FCF Margin (2016 - 2025)

Historic FCF Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2025 value amounting to 487.47%.

  • Agios Pharmaceuticals' FCF Margin rose 7626100.0% to 487.47% in Q4 2025 from the same period last year, while for Dec 2025 it was 698.33%, marking a year-over-year increase of 3744000.0%. This contributed to the annual value of 698.33% for FY2025, which is 3744000.0% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its FCF Margin stood at 487.47% for Q4 2025, which was up 7626100.0% from 696.48% recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' FCF Margin registered a high of 487.47% during Q4 2025, and its lowest value of 12084.01% during Q1 2022.
  • Moreover, its 4-year median value for FCF Margin was 1122.53% (2023), whereas its average is 1808.34%.
  • In the last 5 years, Agios Pharmaceuticals' FCF Margin surged by 103799300bps in 2023 and then crashed by -2262600bps in 2024.
  • Over the past 4 years, Agios Pharmaceuticals' FCF Margin (Quarter) stood at 1537.73% in 2022, then skyrocketed by 33bps to 1023.82% in 2023, then dropped by -22bps to 1250.08% in 2024, then soared by 61bps to 487.47% in 2025.
  • Its FCF Margin stands at 487.47% for Q4 2025, versus 696.48% for Q3 2025 and 626.25% for Q2 2025.